Selenoprotein S (SELENOS) has been implicated in the pathology and progression of numerous conditions, including diabetes, dyslipidemia, obesity, and insulin resistance (IR)—all recognized contributors to endothelial dysfunction (ED), a precursor event to diabetes-induced AS. Here, SELENOS is linked to metabolic syndrome.